Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q

Article metrics

Abstract

Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and have been associated with sensitivity to radio- and chemotherapy as well as favourable prognosis. By using microarray-based expression profiling, we found that oligodendroglial tumours with 1p and 19q losses showed significantly lower expression of the CBP/p300-interacting transactivator with glutamic acid/aspartic acid-rich carboxyl-terminal domain 4 gene (CITED4) at 1p34.2 as compared to tumours without 1p and 19q losses. Mutational analysis showed no CITED4 mutations in gliomas. However, 1p and 19q losses as well as low expression of CITED4 transcripts were significantly associated with hypermethylation of the CITED4-associated CpG island. In line with the latter finding, treatment of CITED4 hypermethylated glioma cell lines with 5-aza-2′-deoxycytidine and trichostatine A resulted in a marked increase of the CITED4 transcript levels. Furthermore, CITED4 hypermethylation was significantly associated with longer recurrence-free and overall survival of patients with oligodendroglial tumours. Taken together, our results indicate that CITED4 is epigenetically silenced in the vast majority of oligodendroglial tumours with 1p and 19q deletions and suggest CITED4 hypermethylation as a novel prognostic marker in oligodendroglioma patients.

Main

Oligodendroglial tumours are primary neoplasms of the central nervous system that frequently demonstrate allelic losses on chromosomal arms 1p and 19q (Reifenberger and Louis, 2003). Recent data indicate that these combined 1p and 19q losses are mediated by an unbalanced t(1;19)(q10;p10) translocation (Griffin et al., 2006; Jenkins et al., 2006). Importantly, 1p/19q deletion is associated with favourable response to radio- and chemotherapy as well as prolonged survival (Cairncross et al., 1998, 2006; van den Bent et al., 2006). Thus, molecular testing for these losses provides clinically valuable information beyond the conventional histologic classification.

To date, several genes located on 1p or 19q have been reported as putative oligodendroglioma-associated tumour suppressor genes. For example, the cyclin-dependent kinase inhibitor 2C (CDKN2C, 1p32) gene is mutated or homozygously deleted in rare cases of anaplastic oligodendroglioma (Reifenberger and Louis, 2003). Other genes showed reduced expression in 1p-deleted gliomas, sometimes associated with promoter hypermethylation but never with mutation. These include the calmodulin-binding transcription activator 1 gene (CAMTA1, 1p36), the DNA fragmentation factor subunit β gene (DFFB, 1p36), the SHREW1 gene (1p36.32), the tumour protein p73 gene (TP73, 1p36.3) and the RAD54 gene (1p32) (Dong et al., 2002; Barbashina et al., 2005; McDonald et al., 2005, 2006). The p190RhoGAP gene (19q13.3) was reported as a candidate tumour suppressor that inhibits PDGF-induced murine oligodendrogliomas (Wolf et al., 2003). However, its role in human oligodendrogliomas is unknown. More recently, the myelin-related epithelial membrane protein gene 3 (EMP3, 19q13.3) was found to be epigenetically silenced in malignant gliomas and neuroblastomas (Alaminos et al., 2005).

We applied microarray-based expression profiling to identify novel genes that are differentially expressed between gliomas with and without 1p/19q losses (Tews et al., 2006). In total, 35 gliomas were studied, including seven oligodendrogliomas WHO grade II, eight diffuse astrocytomas WHO grade II, 14 anaplastic oligodendrogliomas WHO grade III and six anaplastic oligoastrocytomas WHO grade III (Tews et al., 2006). Differentially expressed genes allowing for the discrimination between gliomas with and without 1p/19q losses were revealed by significance analysis of microarrays (SAM) followed by prediction analysis for microarrays (PAM) (Tusher et al., 2001; Tibshirani et al., 2002; Tews et al., 2006). One of the genes with significantly lower expression in 1p/19q-deleted gliomas was the CREB-binding protein (CBP)/p300-interacting transactivator with glutamic acid/aspartic acid-rich carboxyl-terminal domain 4 gene (CITED4) at 1p34.2 (OMIM 606815), which has been linked to cancer-relevant cellular processes (Braganca et al., 2002; Fox et al., 2004). Here, we report on a detailed molecular analysis of CITED4 aberrations in human gliomas and provide evidence for an association of CITED4 hypermethylation with longer survival of oligodendroglial tumour patients.

In total, we investigated tumour samples from 78 patients (40 female and 38 male; mean age at operation: 48 years; range: 11–91 years) with gliomas (21 oligodendrogliomas WHO grade II, three oligoastrocytomas WHO grade II, eight diffuse astrocytomas WHO grade II, 29 anaplastic oligodendrogliomas WHO grade III and 17 anaplastic oligoastrocytomas WHO grade III). The tumours were collected at the Departments of Neuropathology, Heinrich-Heine-University, Düsseldorf, and Charité University Hospital, Berlin, and investigated in an anonymized manner as approved by the local institutional review boards. All tumours were classified according to the WHO classification of tumours of the nervous system (Reifenberger et al., 2000). A tumour cell content of at least 80% was histologically assured for each specimen used for molecular analysis. Extraction of DNA and RNA from frozen tumour samples as well as DNA from leukocytes was carried out as reported elsewhere (van den Boom et al., 2003).

In line with our microarray results (Tews et al., 2006), quantitative real-time reverse transcription–polymerase chain reaction (PCR) analysis of 41 gliomas revealed CITED4 transcript levels reduced by at least 50% relative to non-neoplastic brain tissue in 17 of 21 gliomas (81%) with 1p losses spanning the CITED4 locus (Figure 1a). Twelve of these 17 tumours showed transcript levels reduced by at least 75% relative to non-neoplastic brain tissue when ARF1 was used as the reference gene. When ACTG1 was used as reference, all 17 tumours showed CITED4 transcript levels reduced by more than 75% relative to non-neoplastic brain tissue. In contrast, only 5 of 20 gliomas (25%) with retention of both CITED4 alleles showed reductions in the CITED4 transcript levels by at least 50% relative to non-neoplastic brain tissue (Figure 2). Statistical analyses confirmed that CITED4 mRNA expression was significantly lower (Student's t-test, P<0.001) and more commonly reduced (Fisher's exact test, P<0.001) in 1p/19q-deleted gliomas.

Figure 1
figure1

(a) Examples of results obtained by quantitative real-time reverse transcription-PCR, which was performed on 41 tumours using primers 5′-gggaggacagtttggcttca-3′ and 5′-gggagaggacacgatccaag-3′ for the detection of CITED4 transcripts, SYBR-Green fluorescent dye incorporation and the ABI PRISM 5700 sequence detection system (Applied Biosystems, Foster City, CA, USA). CITED4 expression in each tumour was calculated relative to non-neoplastic brain tissue (BD Biosciences, St Jose, CA, USA) after normalisation to the mRNA levels of ADP-ribosylation factor 1 (ARF1, GenBank accession no. NM_001658, primers: 5′-gaccacgatcctctacaagc-3′ and 5′-tcccacacagtgaagctgatg-3′) or actin-γ (ACTG1, GenBank accession no. NM_001614, primers 5′-cagctctcgcactctgttctt-3′ and 5′-cgacgatggaaggaaacac-3′). Note: reduced level of CITED4 mRNA in a 1p/19q-deleted glioma (AO84) as compared to a glioma without 1p/19q losses (A82) and non-neoplastic brain tissue (NB). Abscissa, cycle number; Ordinate, relative amount of PCR product (RFU, relative fluorescence units). The curves obtained for A82 and NB are nearly identical for ARF1 and CITED4. In AO84, the ARF1 curve is shifted to the left and the CITED4 curve to the right relative to the respective curves for A82 and NB (t, threshold value). The calculated CITED4 mRNA level in AO84 was 20% of the level in NB and A82. (b) Sequencing of the CITED4-associated CpG island after sodium bisulfite treatment of DNA revealed methylation of CpG sites in AO84 (arrowheads in upper lane) but not in A82 and NB (middle lanes). DNA methylated in vitro using SssI (CpG) methylase (NewEngland Biolabs, Beverly, MA, USA) served as a positive control (lower lane). Shown is the reverse sequence from nucleotides g.40997168 to g.40997212 (GenBank accession no. NC_000001). (c) Induction of CITED4 mRNA in three glioma cell lines (A172 and T98G, American Type Culture Collection, Manassas, VA, USA; U138MG, German National Ressource Center for Biological Material, Braunschweig, Germany) by 5-aza-2′-deoxycytidine and trichostatin A treatment as determined by real-time reverse transcription–PCR. Cell lines were grown either under standard conditions (1) or under two different treatment conditions: (2) 500 nM 5-aza-2′-deoxycytidine for 48 h plus 1 μ M trichostatin A for 24 h or (3) 1 μ M 5-aza-2′-deoxycytidine for 72 h plus 1 μ M trichostatin A for 24 h. (d) Results of reverse transcription–PCR analysis of CITED4 expression in A172 cells before (1) and after treatment with 5-aza-2′-deoxycytidine and trichostatin A under two different conditions (see Figure 1c). Note marked induction of CITED4 mRNA after treatment (bp=base pairs).

Figure 2
figure2

Methylation patterns in the 5′-CpG island of CITED4 in 62 gliomas and two samples of non-neoplastic brain tissue (NB1, NB2). Methylation at each of the 54 investigated CpG sites was determined by PCR amplification of two adjacent fragments of the CITED4 CpG island (covering 54 CpG sites between nucleotides 40 996 844 and 40 997 411, Genbank accession no. NC_000001) from sodium bisulfite-modified DNA using primers 5′-tttggttagtttaagttttattttagt-3′ and 5′-aatcacaaaaacccgcaacctataa-3′ as well as 5′-ttataggttgcgggtttttgtgatt-3′ and 5′-acctctacaccaaacgataacc-3′, followed by direct sequencing. The methylation status at each CpG site was rated according to the following scale: 0, not methylated; 1, weakly methylated (intensity of the methylated signal lower than 1/3 relative to the unmethylated signal); 2, moderately methylated (intensity of the methylated signal between 1/3 and 2/3 relative to the unmethylated signal); 3, strongly methylated (intensity of the methylated signal higher than 2/3 of the unmethylated signal). This rating is represented in a grey-scale pattern as indicated below the figure (na, not analysed). Each tumour was assigned to one of two groups: (1) no CITED4 hypermethylation (methylation score 1, 2 or 3 in less than 50% of the investigated CpG sites) or (2) CITED4 hypermethylation (methylation score 1, 2 or 3 in more than 50% of the investigated CpG sites). CITED4 mRNA expression (Expr.) levels relative to non-neoplastic brain tissue were subdivided into two categories as shown below the figure. Allelic losses on 1p and 19q are also indicated for each tumour (+, allelic loss; −, no allelic loss; * allelic loss restricted to distal 1p not including the CITED4 locus). At least five microsatellite loci located on 1p (D1S200, D1S211, D1S507, D1S489, D1S468) and five microsatellite loci located on 19q (D19S572, D19S219, D19S1182, D19S596, D19S210) were assessed for allelic loss in each tumour (Felsberg et al., 2004). The location of exon 1 and the start codon (ATG) are indicated on top of the figure. Note a close association between 1p/19q losses and CITED4 hypermethylation. Furthermore, 15 of 19 tumours with hypermethylation showed CITED4 mRNA levels of <0.5-fold relative to the reference brain tissue, as compared to 7 of 22 tumours without hypermethylation.

Mutation screening of 45 gliomas, including 22 tumours with 1p/19q losses, detected 15 different CITED4 polymorphisms, mostly single nucleotide exchanges (Table 1). Four polymorphisms (c.95T>A: Leu32Gln; c.170G>C, Arg57Pro; c.173A>G, Gln58Arg; c.393C>T, Gly131Gly) were linked to each other, that is, occurred together in nine patients. A 36-base pair in-frame deletion polymorphism (c.327-362del, GenBank accession no. NM_133467.2) was found in two patients, with one patient being constitutionally homozygous for this polymorphism. However, none of the 45 tumours carried somatic mutations, indicating that structural alterations of CITED4 are absent or very rare in gliomas.

Table 1 CITED4 sequence polymorphisms identified in 45 glioma patients

We next investigated the role of aberrant methylation of the CITED4-associated CpG island in 62 gliomas, including the 41 tumours studied for CITED4 expression. CITED4 hypermethylation was detected in 31 of 34 gliomas with 1p/19q losses (91%) but only in 2 of 28 gliomas without 1p/19q losses (7%) (Figures 1b and 2) (Fisher's exact test, P<0.001). CITED4 hypermethylation was absent in leucocyte DNA from 16 patients with CITED4 hypermethylated gliomas and in non-neo;plastic brain samples from two unrelated individuals (Figure 2).

Correlation of CITED4 expression and methylation revealed that CITED4 transcript levels were reduced by at least 50% relative to non-neoplastic brain tissue in 15 of 19 tumours (79%) with CITED4 hypermethylation but only in 7 of 22 tumours (32%) without CITED4 hypermethylation. Statistical analyses confirmed that CITED4 mRNA levels were significantly lower (Student's t-test, P<0.01) and more commonly reduced (Fisher's exact test, P<0.01) in CITED4-hypermethylated gliomas. In line with these findings, 5-aza-2′-deoxycytidine and trichostatin A treatment of three CITED4-hypermethylated glioma cell lines (A172, T98G, U138MG) resulted in markedly increased mRNA levels (Figure 1c–d).

To assess the relationship between CITED4 hypermethylation and patient survival, we investigated 45 patients with oligodendroglial tumours (19 WHO grade II, 26 WHO grade III) and available follow-up data (Felsberg et al., 2004). The median follow-up time after diagnosis was 122 months. Twenty-three patients died of their tumours while 22 patients were still alive at last follow-up. Median overall survival after diagnosis was 103 months, median recurrence-free survival was 42 months. All patients were treated by open resection. Twenty-four of the 26 patients with WHO grade III tumours received adjuvant therapy, comprising radiotherapy in 16 patients, alkylating chemotherapy in one patient, and combined radio- and chemotherapy in seven patients. Univariate statistical analysis revealed that CITED4 hypermethylation was significantly associated with longer recurrence-free and overall survival in the entire group of 45 patients and in the 26 patients with WHO grade III tumours (Figure 3a–d). Similarly, significant associations were found between the 1p/19q allelic status and survival (Figure 3e–h). Multivariate analysis identified CITED4 hypermethylation and 1p/19q deletions as significant prognostic factors adjusted for WHO grade and patient age (Table 2).

Figure 3
figure3

(ad) Significant associations (log rank tests) of CITED4 hypermethylation with longer recurrence-free survival (RFS) and overall survival (OS) in patients with oligodendroglial tumours (meth., CITED4 hypermethylated; no meth., CITED4 not hypermethylated). Shown are Kaplan–Meier survival curves obtained for 45 patients (a, b), including 19 patients with WHO grade II and 26 patients with WHO grade III tumours, as well as in the subgroup of 26 patients with WHO grade III tumours (c, d). (eh) Kaplan–Meier survival curves stratified according to the 1p/19q allelic status in the same patients. Similar to CITED4 hypermethylation, 1p and 19q losses are significantly associated with longer RFS and OS in all 45 patients (e, f) and in the subgroup of 26 patients with WHO grade III tumours (g, h). Kaplan–Meier survival curve estimation and log rank tests were performed with the GraphPad Prism 4 software.

Table 2 Results of multivariate Cox proportional hazards regression analysis based on 45 patients with oligodendroglial tumours (19 patients with WHO grade II and 26 patients with WHO grade III tumours)

The CITED4 gene encodes a 184-amino-acid protein of 24.5 kDa that binds CBP and the tumour suppressor protein EP300 (E1A-binding protein, 300 kDa), functions as a co-activator of the transcription factor AP-2 (Braganca et al., 2002), blocks binding of hypoxia-inducible factor 1 alpha (HIF1α) to EP300 and inhibits HIF1α transactivation as well as hypoxia-mediated reporter gene activation (Fox et al., 2004). Loss of nuclear expression or cytoplasmic translocation of CITED4 has been implicated in breast cancer development (Fox et al., 2004). Here, we report that CITED4 mRNA expression in gliomas is significantly lower in 1p/19q-deleted versus non-deleted tumours. Furthermore, we found reduced expression closely linked to CITED4 hypermethylation. In fact, our data indicate biallelic CITED4 inactivation by loss of one allele and hypermethylation of the other allele in the vast majority of 1p/19q-deleted oligodendroglial tumours. The absence of CITED4 hypermethylation in DNA extracted from leucocytes and non-neoplastic brain tissue indicates that CITED4 is not imprinted. However, it remains unclear whether CITED4 hypermethylation is already present in the yet unknown cell of origin of oligodendrogliomas or represents an acquired aberration selected for during tumorigenesis.

The molecular mechanisms by which CITED4 inactivation might promote oligodendroglial tumour growth are as yet unknown. CITED4 downregulation could interfere with EP300 tumour suppressor activity (Iyer et al., 2004), which, among other functions, plays a crucial role in p53 regulation (Grossman, 2001). Interestingly, 1p/19q-deleted oligodendrogliomas usually lack TP53 mutations (Reifenberger and Louis, 2003). However, further studies need to substantiate a tumour-suppressive function of the CITED4 protein and to clarify the functional consequences of its inactivation in oligodendroglial tumours.

We found a similar prognostic significance of CITED4 hypermethylation in oligodendroglioma patients as obtained for 1p/19q deletion. Thus, diagnostic assessment of CITED4 hypermethylation might be an alternative approach to 1p/19q-testing. However, the frequency of CITED4 hypermethylation in other gliomas, in particular anaplastic astrocytomas and glioblastomas, remains to be determined. Furthermore, future studies need to address whether CITED4 protein expression analysis, for example, by immunohistochemistry, might substitute for methylation analysis and 1p/19q-testing. It also needs to be investigated whether CITED4 inactivation contributes to radio- and chemosensitivity or just represents a surrogate marker for other alterations in 1p/19q-deleted oligodendrogliomas. For example, 1p/19q-deletion has been linked to hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene (Möllemann et al., 2005), which predicts response to alkylating chemotherapy in malignant gliomas (Hegi et al., 2005). Taken together, our results suggest CITED4 as an interesting novel candidate gene in oligodendroglial tumours and should stimulate further research into its functional roles and clinical significance.

Accession codes

Accessions

GenBank/EMBL/DDBJ

Abbreviations

LOH:

loss of heterozygosity

OS:

overall survival

RFS:

recurrence-free survival

WHO:

World Health Organisation

References

  1. Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M et al. (2005). EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65: 2565–2571.

  2. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M . (2005). Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119–1128.

  3. Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC et al. (2002). Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 277: 8559–8565.

  4. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707–2714.

  5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473–1479.

  6. Dong S, Pang JC, Hu J, Zhou LF, Ng H . (2002). Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 98: 370–375.

  7. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al. (2004). Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121–130.

  8. Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC et al. (2004). CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res 64: 6075–6081.

  9. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD et al. (2006). Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988–994.

  10. Grossman SR . (2001). p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 268: 2773–2778.

  11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003.

  12. Iyer NG, Ozdag H, Caldas C . (2004). p300/CBP and cancer. Oncogene 23: 4225–4231.

  13. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852–9861.

  14. McDonald JM, Dunmire V, Taylor E, Sawaya R, Bruner J, Fuller GN et al. (2005). Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. Mol Cancer 4: 35.

  15. McDonald JM, Dunlap S, Cogdell D, Dunmire V, Wei Q, Starzinski-Powitz A et al. (2006). The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther 5: 300–304.

  16. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G . (2005). Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379–385.

  17. R Development Core Team (2005). A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, ISBN 3-900051-07-0, http://www.R-project.org.

  18. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP . (2000). Oligodendroglial tumours and mixed gliomas. In: Kleihues P, Cavence WK (eds). Tumours of the Nervous System – Pathology and Genetics. World Health Organisation Classification of Tumours. IARC Press: Lyon, pp 55–70.

  19. Reifenberger G, Louis DN . (2003). Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111–126.

  20. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G et al. (2006). Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119: 792–800.

  21. Tibshirani R, Hastie T, Narasimhan B, Chu G . (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567–6572.

  22. Tusher VG, Tibshirani R, Chu G . (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116–5121.

  23. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 20: 2715–2722.

  24. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS et al. (2003). Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033–1043.

  25. Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C et al. (2003). p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev 17: 476–487.

Download references

Acknowledgements

This study was supported by grants from the Deutsche Krebshilfe to GR and MS (70-3088-Sa1) as well as to GR and AvD (70-3163-Wi3), and from the German Bundesministerium für Bildung und Forschung (BMBF) within the National Genome Research Network 2 (NGFN-2) to PL, MH, GR, CH and AvD (01GS0460, 01GS0462 and 01GS0463). BT was a scholar of the Studienstiftung des Deutschen Volkes.

Author information

Correspondence to G Reifenberger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tews, B., Roerig, P., Hartmann, C. et al. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene 26, 5010–5016 (2007) doi:10.1038/sj.onc.1210297

Download citation

Keywords

  • CITED4
  • gene expression profiling
  • oligodendroglioma
  • CpG island
  • hypermethylation
  • tumour suppressor gene

Further reading